Lisdexamfetamine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription central nervous system stimulant (Schedule II controlled substance) approved for ADHD and moderate-to-severe binge eating disorder. A prodrug that requires enzymatic cleavage in the bloodstream to release the active moiety dextroamphetamine, providing a smoother onset and more consistent duration of action with potentially lower abuse liability compared to immediate-release amphetamines. Dosage must be determined by your prescribing physician.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription central nervous system stimulant (Schedule II controlled substance) approved for ADHD and moderate-to-severe binge eating disorder. NutriStack rates the supporting evidence as strong. Common adult dosing is 20–70 mg daily in the morning (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: improved attention and focus, reduced binge eating episodes, smoother onset than ir amphetamines. 10 sources indexed (2014–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Lisdexamfetamine is an inactive prodrug consisting of dextroamphetamine covalently bound to the amino acid lysine. After oral absorption, it is enzymatically hydrolyzed by red blood cell aminopeptidases to release active dextroamphetamine, which promotes release and inhibits reuptake of dopamine and norepinephrine. The prodrug design limits the rate of active drug delivery regardless of dose.1,2
Dosing & protocol.
Can be taken with or without food. Capsules may be opened and dissolved in water, orange juice, or yogurt. Take in the morning to avoid insomnia.
Full safety detail.
Side effects
- Decreased appetite
- Insomnia
- Dry mouth
- Headache
- Tachycardia and increased blood pressure
- Anxiety and irritability
- Nausea
- Weight loss
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
2- 1Lisdexamfetamine's Efficacy in Treating Attention Deficit Hyperactivity Disorder (ADHD): A Meta-Analysis and ReviewPMIDRutledge-Jukes H, Jonnalagadda P, McIntosh AP et al. · Cureus · 2024
Rutledge-Jukes H, Jonnalagadda P, McIntosh AP et al.. Lisdexamfetamine's Efficacy in Treating Attention Deficit Hyperactivity Disorder (ADHD): A Meta-Analysis and Review. Cureus. 2024
- 2Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHDPMIDManeeton N, Maneeton B, Suttajit S et al. · Drug design, development and therapy · 2014
Maneeton N, Maneeton B, Suttajit S et al.. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Drug design, development and therapy. 2014
Randomized controlled trials
3- 3Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled TrialPMIDGrilo CM, Ivezaj V, Tek C et al. · The American journal of psychiatry · 2025
Grilo CM, Ivezaj V, Tek C et al.. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. The American journal of psychiatry. 2025
- 4Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trialPMIDEzard N, Clifford B, Siefried KJ et al. · Addiction (Abingdon, England) · 2025
Ezard N, Clifford B, Siefried KJ et al.. Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial. Addiction (Abingdon, England). 2025
- 5A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHDPMIDMadaan V, Bhaskar S, Donnelly GAE et al. · Journal of attention disorders · 2024
Madaan V, Bhaskar S, Donnelly GAE et al.. A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD. Journal of attention disorders. 2024
Reviews & position papers
1- 6[Methylphenidate and lisdexamfetamine toxicity in a patient with ADHD after gastric bypass]PMIDDoyle A, Stes S, Berkmans E et al. · Tijdschrift voor psychiatrie · 2025
Doyle A, Stes S, Berkmans E et al.. [Methylphenidate and lisdexamfetamine toxicity in a patient with ADHD after gastric bypass]. Tijdschrift voor psychiatrie. 2025
Reference material
4- 7Cortese S et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018.Source linkedPMID
- 8McElroy SL et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: a randomized clinical trial. J Clin Psychiatry. 2015.Source linkedPMID
- 9Costa GPA et al. Pharmacotherapies for Binge Eating Disorder: Systematic Review and Network Meta-Analysis. Obes Rev. 2025.Source linkedPMID
- 10Coghill DR, Caballero B, Sorooshian S et al.. A systematic review of the safety of lisdexamfetamine dimesylate. CNS drugs. 2014Source linkedPMID
Common questions.
Quick answers about Lisdexamfetamine, drawn from the data on this page.
What is Lisdexamfetamine?
Prescription central nervous system stimulant (Schedule II controlled substance) approved for ADHD and moderate-to-severe binge eating disorder. A prodrug that requires enzymatic cleavage in the bloodstream to release the active moiety dextroamphetamine, providing a smoother onset and more consistent duration of action with potentially lower abuse liability compared to immediate-release amphetamines. Dosage must be determined by your prescribing physician.
What is Lisdexamfetamine used for?
Commonly cited benefits of Lisdexamfetamine include: Improved attention and focus; Reduced binge eating episodes; Smoother onset than IR amphetamines; Longer and more consistent duration; Lower abuse potential due to prodrug design. NutriStack rates the overall evidence as strong.
What is a typical dose of Lisdexamfetamine?
A typical adult dose of Lisdexamfetamine is 20–70 mg daily in the morning (as prescribed by your physician). The commonly recommended form is Capsule or chewable tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Lisdexamfetamine?
Reported side effects include decreased appetite, insomnia, dry mouth, headache, tachycardia and increased blood pressure, anxiety and irritability. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Lisdexamfetamine?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Lisdexamfetamine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.